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Abstract
Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a
novel mechanism of action in over 40 years, has already been detected in Mycobacterium
tuberculosis. As a new drug, however, there is currently insufficient clinical data to facilitate
reliable and timely identification of genomic determinants of resistance. Here we investigate
the structural basis for M. tuberculosis associated bedaquiline resistance in the drug target,
AtpE. Together with the 9 previously identified resistance-associated variants in AtpE, 54
non-resistance-associated mutations were identified through comparisons of bedaquiline
susceptibility across 23 different mycobacterial species. Computational analysis of the
structural and functional consequences of these variants revealed that resistance associ-
ated variants were mainly localized at the drug binding site, disrupting key interactions with
bedaquiline leading to reduced binding affinity. This was used to train a supervised predic-
tive algorithm, which accurately identified likely resistance mutations (93.3% accuracy).
Application of this model to circulating variants present in the Asia-Pacific region suggests
that current circulating variants are likely to be susceptible to bedaquiline. We have made
this model freely available through a user-friendly web interface called SUSPECT-BDQ,
StrUctural Susceptibility PrEdiCTion for bedaquiline (http://biosig.unimelb.edu.au/suspect_
bdq/). This tool could be useful for the rapid characterization of novel clinical variants, to
help guide the effective use of bedaquiline, and to minimize the spread of clinical resistance.
Introduction
Tuberculosis (TB) is the leading cause of infectious disease death worldwide, with over 10 mil-
lion new cases and 1.6 million deaths in 2017 [1]. A disproportionate burden arises from the
estimated 558,000 annual cases of rifampicin resistant TB (RR-TB) with 82% being multi-drug
resistant (MDR), which is associated with lengthy, toxic therapy and high rates of mortality
[1]. With limited therapeutic options available, especially for MDR-TB and extensively drug-
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resistant (XDR) TB, the introduction of new treatment options is urgently required. Bedaqui-
line, a new anti-TB drug with a novel mechanism of action, targeting the c-ring of ATP
synthase (AtpE) [2], was approved for treatment for MDR-TB in 2012 [3, 4]. This innovative
drug is potent against both actively replicating and dormant bacilli and has been shown to
increase culture conversion in patients with MDR-TB [5]. The use of bedaquiline has
expanded considerably in recent years, and has been recommended for more routine use in
MDR-TB regimens [6], however clinical failures have already been observed [7, 8]. This neces-
sitates a better understanding of how variants result in resistance to aid in the early detection
of resistance.
Phenotypic, and increasingly genotypic, drug susceptibility testing (DST) is recognized as
essential for effective individualization of TB therapy. However, while progress has been made
in strengthening laboratory diagnostics, the TB community is still struggling to build up labo-
ratory networks with the needed capacity for routine culture and DST [7, 9]. The World
Health Organization (WHO) has strongly urged the development of accurate and reproducible
DST for bedaquiline and recommended that in the absence of specific DST, bedaquiline resis-
tance should be monitored through MIC assessment [10] with resistance development evalu-
ated in patients with treatment failure or relapse. Early characterization of drug resistance
mutations would assist TB patient management and avoid treating individuals with ineffective
toxic regimens [11, 12], but capacity for rapid genotypic prediction of bedaquiline resistance is
limited by the identification of few known resistance associated variants [13].
In an era of rapidly expanding use of molecular technologies, including whole genome
sequencing, tools for evaluating the impact of novel mutations are increasingly vital, particu-
larly for drug resistance to novel and emerging medications such as bedaquiline. Though cul-
ture-based detection of resistance will remain the gold standard, in silico analyses can support
informed decision-making. We have previously shown that the analysis of how variants can
affect protein structure and function can be used to reliably characterize how variants lead to
drug resistance [14–18]. Using this approach, we have shown that drug resistant mutations
can be rapidly, accurately and pre-emptively predicted, guiding drug development [19–22]
and clinical diagnosis [23].
In-vitro selection [24] and clinical studies [25] have shown that variants in the atpE gene
can lead to bedaquiline resistance. To support rapid identification of potential bedaquiline
resistance mutations, we considered whether structural information of the drug target could
help guide clinical inference on genomic variants. Using a suite of well-established computa-
tional tools for characterizing the molecular consequences of mutations on protein structure
and function, we have assessed the effects of mutations on the biophysical changes of AtpE
folding, stability and on drug binding affinity. This was used to characterize how mutations in
AtpE lead to resistance, and to train a predictive multilayer perceptron (feedforward artificial
neural network) algorithm to characterize novel AtpE variants.
Methods
Data sets
Resistant variants from in-vitro selection studies were curated [13, 24, 26] along with a natural
variant [4, 27] and used for model development. Susceptible variants were identified using a
novel homology approach, where the genomes of all mycobacteria species sensitive to the drug
[28] were aligned, therefore inferring that any present variants were likely to be susceptible.
Clinically observed bedaquiline resistant atpE variants were curated from published reports
[25]. The Vietnam dataset consists of whole genome sequences of 1635 Mycobacterium tuber-
culosis (Mtb) strains isolated from patients with pulmonary TB in Ho Chi Minh City, Vietnam.
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Homology modeling of AtpE
The structure of Mtb AtpE was modelled with MODELLER [30] using the experimental crystal
structure of Mycobacterium phlei (M. phlei) AtpE (PDB ID: 4V1F). The model was then mini-
mized in Prime and bedaquiline docked into the apo structure using Glide (Schro¨dinger
Suite).
Modelling the biophysical consequences of missense variants
The structural consequences of the AtpE polymorphisms were assessed to account for all the
potential effects of the mutations. The effects of mutations on protein folding and stability
were assessed using SDM [31], mCSM-Stability [32] and DUET [33], and their effects on pro-
tein flexibility and conformation was predicted using normal mode analysis by DynaMut [34].
The effect of the difference on the protein-protein interactions between the protomers of AtpE
were predicted using mCSM-PPI [32]. The effect of the changes on the binding affinity of
bedaquiline towards AtpE were predicted using mCSM-Lig [35–37]. These approaches are
novel machine-learning algorithms that use graph-based signatures to represent the structural
and chemical environment of the wild-type 3D structure of a protein to quantitatively predict
the effects of point mutations. Additionally, SNAP2 [38] was used to provide additional evolu-
tionary based information.
Machine learning
To build the binary classifier, a multilayer perceptron neural network algorithm was trained,
based on the implementation available through the Weka toolkit [39]. The resistant variants
were up-sampled to create a more balanced model [40]. The training dataset constituted of 50
non-resistant associated variants and 5 resistant associated variants, while the blind test dataset
constituted of 4 non-resistant associated variants and 4 resistant associated variants. To avoid
over-biasing, the train and blind test dataset were non-redundant with respect to residue posi-
tion. The model was trained and evaluated using jackknife [41] and leave-one-residue-posi-
tion-out validation. The classification model was evaluated based on metrics, including the
Area Under the ROC curve (AUC), precision and accuracy. Statistical analysis was performed
using RStudio (version 3.1.1).
Webserver development
The server front-end was built using materialize CSS framework version 1.0.0, while the back-
end was built in Python via the Flask framework (version 0.12.2). It is hosted on a Linux server
running Apache.
Results
We used a structure-guided approach to understand the protein structure of the drug target
AtpE and machine learning to build an empirical tool that could identify likely resistant muta-
tions. The pipeline used to analyze the variants and train a multilayer perceptron neural net-
work algorithm is shown in Fig 1.
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Structural information: The drug binding domain
A homology model of Mtb H37Rv AtpE was built using the existing experimental crystal struc-
ture of AtpE from Mycobacterium phlei (PDB ID: 4V1F) [42], which shares a high sequence
identity with the Mtb protein (84.9%). The protomer model was an alpha helical hairpin struc-
ture comprising two membrane-spanning helices connected by a hydrophilic loop. The homo-
oligomeric construct was built using the M. phlei structure as a guide, as the Mtb protein has
been previously shown to assemble as a homo-nonamer [43] (Fig 2A and 2B). The cylindrical
palisade model contained an internal hydrophobic cavity where phospholipid had been pro-
posed to bind. The conserved proton binding residue (E61) was located sandwiched between
adjacent protomers and equidistantly distributed along the center of the hydrophobic mem-
brane bilayer.
The top docking poses of bedaquiline with the nonamer homology model identified a pose
consistent with that observed in the M. phlei structure. The drug binding cleft was located at
the interface of two protomers, with amino acid residues E61, A62, Y64, F65 from one proto-
mer and I66 from the adjacent protomer defining the drug binding cleft. Analysis of the
molecular interactions with Arpeggio [44] highlighted a strong network of polar interactions
between the drug and AtpE (Fig 2C). Of particular interest, the diethylaminomethyl group of
bedaquiline specifically interacted with the conserved proton binding residue E61, making
Fig 1. Methodology. This workflow highlights important steps in the methodology and how the main components of
the algorithms are computed. In our analysis we used 54 non-resistant associated mutations and 9 resistant mutations
for the biophysical analysis, followed by training and validation of our empirical model using a supervised machine
learning algorithm.
https://doi.org/10.1371/journal.pone.0217169.g001
Fig 2. Structure and sequence information. (A) ConSurf analysis of AtpE (M. tuberculosis) where the evolutionary
rates of conservation are color-coded on to the structure. (B) The experimental crystal structure of AtpE bound to
Bedaquiline (purple). (C) The key molecular interaction between Bedaquiline (ball and stick representation; purple)
and AtpE: ionic bond (yellow), π-interactions (green), proximal hydrogen bond (red) and weak polar van der Waal
clashes (orange). The known resistance mutations are shown as salmon red (sticks) on the cartoon representation of
the AtpE structure.
https://doi.org/10.1371/journal.pone.0217169.g002
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tight ionic and hydrogen bonds with the carboxyl group of E61 (S1 Fig). In the docked model,
bedaquiline also made strong π-interactions with residues Y64 and I66, and a hydrogen bond
to A62.
Variant calling
We identified 9 previously published bedaquiline resistant non-synonymous single nucleotide
variants (nsSNVs) from in-vitro selection experiments [4, 13, 24, 26]. To identify AtpE muta-
tions not associated with drug resistance, we examined sequence variation amongst AtpE
sequences from 23 mycobacterial species that have been shown to be phenotypically sensitive
to the drug [27, 45–49] (Fig 3). Due to the high degree of sequence conservation across myco-
bacterial AtpE sequences (~ 66% sequence homology; Clustal Omega), variations between
strains shown to be susceptible to bedaquiline were inferred to not be associated with drug
resistance. Through comparison against the Mtb sequence (highlighted in yellow in Fig 3), 54
non-resistance-associated variants were identified (shown in teal in Fig 3).
Understanding the structural basis of resistance is important to facilitate the rapid identifi-
cation of novel resistance variants, aiding efforts to minimize the rapid development of resis-
tance [23]. The 54 non-resistance-associated variants (“S”) and 9 resistant variants (“R”) were
mapped on the protein structure of AtpE (Fig 1). Most of the non-resistance-associated muta-
tions were located on the N-terminal surface exposed inner loop of AtpE. Conserved regions
(highlighted red in Fig 3) were evident, mainly on the C-terminal or the outer loop and
embedded in the lipid bilayer of the membrane. All resistance-associated mutations were local-
ized within 5 Å of the known drug binding site, which we refer to as the “resistance hotspot”.
Structural and biophysical consequences of AtpE variants
The resistant associated variants were all predicted by SNAP2 [38] to be more functionally del-
eterious than the non-resistance associated variants, reflecting the resistant associated variants
are in a more conserved region of the protein. In order to better understand the molecular
consequences of the mutations on AtpE structure and function, the mutations were analyzed
in the context of both the apo and complexed protomeric structures. The impact of resistant
and non-resistant associated mutations on protein folding, stability and conformation were
assessed using SDM [31], mCSM-Stability [32], DUET [33] and DynaMut [34]. The effect of
the variants on the affinity of the protomers to form the cylindrical palisade homo-oligomer
were examined using mCSM-PPI [32], and the effect of the variants on the binding affinity for
bedaquiline were assessed using mCSM-Lig [37].
Fig 3. Non-resistant associated variant assignment. This image highlights the sequence alignment of 23
mycobacterial species sensitive to Bedaquiline. Residues that were different to the reference M.tuberculosis sequence
(in yellow) are highlighted in teal, and were chosen as non-resistant associated variants for building the empirical
model. The conserved residues are shown in red. The secondary structure of the AtpE protein is shown above the
sequences in blue (α = alpha helix, η = loop). This image was created using ESPript 3 [56].
https://doi.org/10.1371/journal.pone.0217169.g003
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Analysis of the variant effects on protomer stability and the formation of the cylindrical pal-
isade did not reveal statistically significant differences between resistant and non-resistance-
associated variants (Fig 4). This is consistent with recent work that showed in order to mini-
mize fitness costs, resistant associated variants in drug targets tended to have mild effects on
protein stability [50]. The largest destabilizing effect observed amongst the resistance-associ-
ated variants using mCSM-Stability and DUET was for the conservative mutation E61D
(ΔΔG = -1.1 Kcal/mol), however normal mode analysis by DynaMut suggested that the E61D
mutation would not destabilize the structure and was only associated with mild conforma-
tional changes (S1 Fig). Examination of residue conservation across 150 homologous
sequences using ConSurf [51] showed the equivalent residue position in many species was an
Asp, suggesting its introduction is unlikely to have a large structural or functional effect.
While all nine resistant variants were within 5Å of the ligands, five in particular, A63M,
A63P, E61D, L59V and I66M, were within 2.5Å and making direct interactions with bedaqui-
line. Modelling of these mutations revealed that most of them would result in complete loss of
these intermolecular interactions (S2 Fig). For example, E61 upon mutation to Asp would
result in loss of these strong ionic and hydrogen bonds with bedaquiline. Interestingly, the
mutation of I66 to Met and L59 to Val mutation revealed the formation of new interactions,
although the overall binding affinity was predicted to be lower by CSM-lig. Most of the non-
resistant associated variants were located distal to the bedaquiline binding site.
Analysis of predicted changes in bedaquiline binding affinity upon mutation using mCSM-
Lig revealed a significant difference between variants associated with resistance or not associ-
ated with resistance (Fig 4). The non-resistance associated variants were associated with mild
mCSM-Lig predicted changes in bedaquiline binding affinity (average of -0.25 log affinity fold
change). This would be consistent with the mutations leading to minimal change in, or even
increasing, drug binding affinity. The average predicted log fold change in binding affinity
obtained for the 9 resistant mutations, by contrast, was -1.29 log affinity fold change, indicating
that they would likely disrupt bedaquiline binding. Among them, all four D28 resistant variants
were predicted to the largest destabilising effect on bedaquiline binding (-2.5 log affinity fold
change on average). D28 is positioned on the inner helix of the protomer and is 4.7Å from the
drug binding site. When D28 was substituted with either Ala or Gly, a loss in inter-helical inter-
actions and a gain in flexibility was observed, and when substituted to Pro and Val it led to a
gain in intra-molecular interactions and rigidification of the AtpE structures (S2 Fig).
Fig 4. PCA analysis. Boxplot representation of all the features used to build the predictive model. The resistant
associated mutations (R) are represented as red and the non-resistant associated mutations (S) as teal. (� p<0.05, ��
p<0.005, ��� p<0.0001, NS p>0.5 by Welch two sample t-test).
https://doi.org/10.1371/journal.pone.0217169.g004
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Machine learning algorithm: Multilayer perceptron network
Building on this structural analysis, we tested whether these structural features could be used
to train a supervised machine learning algorithm capable of accurately predicting resistant
associated variants. To avoid over-training, the 54 non-resistant and 9 resistant variants were
split into a training and blind test dataset. Our training dataset constituted of 50 non-resistant
associated variants and 5 resistant associated variants (A63V, A63P, I66M, L59V, E61D). Due
to the small sample size, to balance the dataset, the resistant variants in the training dataset
were oversampled (duplicated). The remaining 4 resistant (all D28 mutations) and 4 non-resis-
tant associated (I11L, L15T, A34Q and A45S) variants in the blind test were positioned non-
redundant with those in the training.
A list of features tested in method development is described in S1 Table. As discussed
above, the features that best distinguished between the classes include distance from ligand
binding site (“Distance from Ligand”, p< 0.0001), mCSM-Lig (p = 0.026) and SNAP2
(p< 0.0001) (Fig 4). Using jackknife and leave-one-residue-position-out validation, models
trained using multilayer perceptron neural networks yielded the strongest balanced perfor-
mance. The final model correctly classified 93.33% and 100% of variants in the training and
blind test datasets respectively (Fig 5, Table 1). The comparative performance across iterative
non-redundant blind datasets suggested that the model was not over-fitted.
The classifier revealed that variants with mild effects on protein stability and conformation
(DynaMut < 0.28 Kcal/mol and DUET < -1.65 Kcal/mol), located close to the docked beda-
quiline (distance from ligand < 6.36 Å) were likely to be associated with resistance. A closer
examination of the four incorrectly classified non-resistant associated variant in the train data-
set revealed that three of them, G58S, A63T and L68V, were positioned very close to the beda-
quiline binding site (< 2.5 Å) and N33A had a large predicted change in binding affinity (-1.4
log affinity fold change); indicating that these mutations might have direct consequences on
bedaquiline binding.
Fig 5. Evaluation metric. The ROC curve shows that using the structural and functional consequences of the variants,
we were able to accurately identify resistant (red) and non-resistant associated (teal) variants.
https://doi.org/10.1371/journal.pone.0217169.g005
Table 1. Evaluation metrics of the train and blind test dataset.
Multilayer Perceptron (MLP) Precision score Recall F-measure ROC area PRC area
Train Dataset 0.952 0.933 0.938 0.970 0.967
Blind test Dataset 1.000 1.000 1.000 1.000 1.000
https://doi.org/10.1371/journal.pone.0217169.t001
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Clinically identified resistance associated variants
Using a model trained without the D28 variants, we analyzed the recently reported clinical
atpE bedaquiline resistant variants [25]. Both D28N and A63V were both predicted by the
model to lead to bedaquiline resistance, consistent with the clinical data. Looking at these
mutations within the structure, the mutation at D28 would disrupt interactions made by the
wild-type residue to bedaquiline, consistent with the mCSM-Lig predictions that it would lead
to a significant reduction in ligand binding affinity (S3 Fig; -1.87 log affinity fold change).
Interestingly, while A63 did not make interactions directly with bedaquiline, the mutation to
Val would lead to steric clashes with the bound ligand and prevent bedaquiline binding (S3
Fig).
Vietnam data analysis
We also used this approach to predict the sensitivity of two atpE nsSNVs, I16V and P52L,
identified through whole genomic sequencing of Mtb strains isolated from 1635 TB patients in
Vietnam [15]. The predictive tool classified the reported nsSNPs to be non-resistant associated
variants. These variants were located approximately 10 Å away from the bedaquiline binding
site, and mutations at these residues were not predicted to disrupt any interactions with beda-
quiline (S4 Fig). As these samples had been collected from patients that had not been adminis-
tered bedaquiline, it provided confidence that in our large analysis of patients in Vietnam
there were no circulating strains likely to be resistant to bedaquiline.
SUSPECT-BDQ webserver
We have implemented SUSPECT-BDQ as a user-friendly, freely available web server http://
biosig.unimelb.edu.au/suspect_bdq/. SUSPECT-BDQ provides two different input options.
The “Single Mutation” option allows users to predict whether a mutation will be characterized
as either Resistant or Susceptible. For this option, the server requires the point mutation to be
specified as a text string containing the wild-type residue one-letter code, its corresponding
position on the structure and the mutant one-letter code. The “Mutation List” option allows
the user to upload a file with a list of mutations in a file for batch processing. In order to assist
users to submit their mutations for analysis, sample submission entries are available for both
input options and a help page is also available via the top navigation bar.
For the “Single Mutation” option, the web server displays the prediction outcome of SUS-
PECT-BDQ alongside with details of the user input data, information on the residue environ-
ment and parameters used on the prediction (S5 Fig). In addition, an interactive 3D viewer,
built using NGL [52] allows for analysis of non-covalent inter-residue interactions for the posi-
tion specified in the input calculated with Arpeggio [44] for wild-type and mutant structures.
For the “Mutation List” option, the results are summarized in a downloadable table from
which users can access details for each single mutation. A 3D viewer is also shown and each
wild-type residue from the input list is colored according to the predicted effect.
Discussion
Early genomic detection of resistance is crucial for tailoring individual therapy and preventing
the onward transmission of resistant infection. This is especially of importance to limit the
spread of resistance to bedaquiline, one of the few treatment options for XDR-TB. While sig-
nificant progress has been made in terms of innovative tools to understand and quantify the
different range of effects in which a mutation or a set of mutations can give rise to a drug-resis-
tant phenotype, a gap still exists when integrating these predictions and drawing conclusions
Empirical ways to identify novel Bedaquiline resistance mutations in AtpE
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regarding causality and the strength of associations observed. This is compounded by the need
for detailed information regarding the system/protein. The availability of scalable, effective
computational methods to assess mutational effects creates new opportunities for developing
integrated approaches and deciphering complex genomic background patterns, shedding light
on their role in the emergence of a given phenotype and molecular mechanisms of action [19].
Here we have used a computational approach to better understand the molecular mecha-
nism of drug resistance within the context of the protein’s 3D structure. A machine learning
algorithm was used to build a predictive tool which could pre-emptively determine novel beda-
quiline resistant mutations within atpE. We began our investigation by studying the interac-
tion dynamics between the c-ring of ATP synthase bound to bedaquiline. The correlations of
conformational changes and Gibb’s free energy provided novel molecular insights into how
resistance variants affected bedaquiline binding but led to minimal disruption of protein fold-
ing and dynamics. Mapping of all the mutations on the crystal structure helped us identify the
“mutational hotspot” for AtpE, which was in proximity to the drug binding site. We saw that
resistance associated variants were more likely to be located within this resistance hotspot, and
lead to a significant disruption in bedaquiline binding. Interestingly, the characterized resis-
tant variants did not lead to large changes in protein folding, stability or oligomeric state,
which would impose a larger fitness penalty [50].
This in silico biophysical information was used to build a predictive algorithm that accu-
rately identified resistant mutations. We then prepared a comprehensive mutational dataset
that contained the predictions of all possible mutations in AtpE, which we have made available
through a web-based interface: SUSPECT_BDQ (http://biosig.unimelb.edu.au/suspect_bdq/).
These analyses highlight the power of considering the structural environment of a mutation to
understand the molecular and biological consequences [53]. As a relatively novel drug, there is
still a paucity of reliable information regarding resistance mutations. While limited by the rela-
tively small available datasets, repeated stratified non-redundant blind testing revealed the
model was very robust. This associative approach thus helped us establish a set of guidelines
which adds to the missing information in the database for new TB drugs like bedaquiline. It
also provides a molecular understanding of how variants in AtpE affect ligand binding, leading
to resistance, providing insight to guide development of second-generation inhibitors.
We intend further development of this tool through expanded genomic targets, and evalua-
tion using additional clinical isolates. In particular we intend to extend SUSPECT_BDQ to
include non-target based resistance to bedaquiline, which has been linked to mutations in
Rv0678 [54], a transcriptional repressor of the gene encoding the MmpS5-MmpL5 efflux
pump, and pepQ (Rv2535c) [55], a putative Xaa-Pro aminopeptidase. Both are associated with
low-level of resistance and therefore we did not include them in the study. However, low level
resistance may have clinical significance in some settings, and future work will further evaluate
other potentially important loci. Additionally, testing this tool on further clinical isolates will
enhance the efficiency of the tool to predict the consequences of novel mutations.
Conclusion
This novel computational approach can enhance the impact of genome sequencing in identify-
ing and characterizing variants more accurately and may therefore assist in guiding optimal
usage of bedaquiline. The results obtained from our empirical tool is promising and should
help facilitate routine genotypic drug susceptibility testing for bedaquiline and stimulate fur-
ther research to help avoid the emergence of resistance to this new treatment through early
detection.
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Supporting information
S1 Table. The list of different features used to build the empirical model for predicting
novel resistance associated mutations in bedaquiline.
(PDF)
S1 Fig. Detailed molecular interactions between the key proton binding residue E61, and
upon its mutation to Asp, with bedaquiline. The wild-type residue is shown in cyan and
mutant in salmon red in ball and stick representation. Bedaquiline is shown in purple (ball
and stick representation). Hydrogen bonds are shown as orange dashes and ionic bond in yel-
low.
(TIF)
S2 Fig. Images of intermolecular interactions made by the wild-type residue (shown as
cyan) and the mutant amino acid (shown as salmon red). Hydrogen bonds are shown in
red, halogen bonds in blue, ionic bonds in yellow, hydrophobic bonds in green, π bonds in
grey.
(TIF)
S3 Fig. Detailed molecular interactions between two clinically observed bedaquiline resis-
tant variants, with the drug. The wild type residue is shown in cyan and mutant in salmon
red in ball and stick representation. Bedaquiline is shown in purple (ball and stick representa-
tion). Halogen bonds are represented in blue dashes (amide-amide interaction) and π-bond as
grey dashes.
(TIF)
S4 Fig. The localization of two circulating atpE variants relative to the bedaquiline binding
pocket. The wild type residues are shown in cyan and mutant in salmon red in ball and stick
representation. Bedaquiline is shown in purple (ball and stick representation).
(TIF)
S5 Fig. SUSPECT-BDQ webserver. Web-server results page for a single point mutation pre-
diction. The predicted outcome is shown alongside with complementary information on the
submitted mutation. An interactive 3D viewer allows for analysis of non-covalent interactions
for both the wild type and mutant residue. In both cases controllers are provided in order to
hide or show specific interactions and customize molecule representation.
(TIF)
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